Mesoporous silica coated SPIONs containing curcumin and silymarin intended for breast cancer therapy.

Soosan Sadegha, Reyhaneh Varshochian, Pegah Dadras, Hosniyeh Hosseinzadeh, Ramin Sakhtianchi, Zahra Hadavand Mirzaie, Akram Shafiee, Fatemeh Atyabi, Rassoul Dinarvand
Author Information
  1. Soosan Sadegha: Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  2. Reyhaneh Varshochian: Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  3. Pegah Dadras: Trita Nanomedicine Research Center (TNRC), Trita Third Millennium Pharmaceuticals, Zanjan, Iran.
  4. Hosniyeh Hosseinzadeh: Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  5. Ramin Sakhtianchi: Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  6. Zahra Hadavand Mirzaie: Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  7. Akram Shafiee: Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  8. Fatemeh Atyabi: Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  9. Rassoul Dinarvand: Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. dinarvand@tums.ac.ir. ORCID

Abstract

INTRODUCTION: Super-paramagnetic iron oxide nanoparticles (SPIONs) are known as promising theranostic nano-drug carriers with magnetic resonance imaging (MRI) properties. Applying the herbaceous components with cytotoxic effects as cargos can suggest a new approach in the field of cancer-therapy. In this study mesoporous silica coated SPIONs (mSiO2@SPIONs) containing curcumin (CUR) and silymarin (SIL) were prepared and evaluated on breast cancer cell line, MCF-7.
METHODS: Nanoparticles (NPs) were formulated by reverse microemulsion method and characterized by DLS, SEM and VSM. The in vitro drug release, cellular cytotoxicity, and MRI properties of NPs were determined as well. The cellular uptake of NPs by MCF-7 cells was investigated through LysoTracker Red staining using confocal microscopy.
RESULTS: The MTT results showed that the IC50 of CUR + SIL loaded mSiO2@SPIONs was reduced about 50% in comparison with that of the free drug mixture. The NPs indicated proper MRI features and cellular uptake through endocytosis.
CONCLUSION: In conclusion the prepared formulation may offer a novel theranostic system for breast cancer researches.

Keywords

References

  1. Chemosphere. 2013 Jul;92(6):681-7 [PMID: 23618346]
  2. Colloids Surf B Biointerfaces. 2016 Jul 1;143:224-232 [PMID: 27015647]
  3. Adv Drug Deliv Rev. 2011 Jan-Feb;63(1-2):24-46 [PMID: 20685224]
  4. Sci Rep. 2017 Apr 19;7:46513 [PMID: 28422155]
  5. J Tissue Eng. 2013 Sep 03;4:2041731413503357 [PMID: 24020012]
  6. Toxicol Appl Pharmacol. 2011 Jun 1;253(2):81-93 [PMID: 21435349]
  7. Int J Nanomedicine. 2012;7:753-62 [PMID: 22393284]
  8. Chemistry. 2009 Jun 2;15(23):5661-5 [PMID: 19396886]
  9. Oncol Rep. 2015 Jun;33(6):2711-8 [PMID: 25891311]
  10. Sci Rep. 2016 Jun 14;6:27847 [PMID: 27297588]
  11. Cancer Res. 2007 Mar 1;67(5):2022-9 [PMID: 17332330]
  12. Drug Deliv Transl Res. 2012 Aug;2(4):284-92 [PMID: 23110256]
  13. Adv Colloid Interface Sci. 2003 Apr 25;103(2):121-47 [PMID: 12706552]
  14. J Pharm Biomed Anal. 1997 Aug;15(12):1867-76 [PMID: 9278892]
  15. Int J Pharm. 2015 Oct 15;494(1):430-44 [PMID: 26315125]
  16. Chem Rev. 2012 Apr 11;112(4):2323-38 [PMID: 22216932]
  17. Carcinogenesis. 2005 Aug;26(8):1450-6 [PMID: 15831530]
  18. Sci Rep. 2013;3:2534 [PMID: 23982586]
  19. Pharmaceuticals (Basel). 2022 Apr 27;15(5): [PMID: 35631363]
  20. Langmuir. 2012 Jun 5;28(22):8479-85 [PMID: 22578053]
  21. Molecules. 2015 Aug 05;20(8):14293-311 [PMID: 26251892]
  22. Int J Nanomedicine. 2012;7:3503-16 [PMID: 22848174]
  23. Biofactors. 2013 Jan-Feb;39(1):37-55 [PMID: 22996381]
  24. Indian J Pharm Sci. 2009 Mar;71(2):139-42 [PMID: 20336212]
  25. ACS Appl Mater Interfaces. 2013 Jun 12;5(11):5219-26 [PMID: 23672213]
  26. Altern Med Rev. 2009 Jun;14(2):141-53 [PMID: 19594223]
  27. J Cancer. 2016 Jun 23;7(10):1250-7 [PMID: 27390600]
  28. Hum Exp Toxicol. 2017 Jun;36(6):573-586 [PMID: 27402681]
  29. Biomaterials. 2007 Mar;28(9):1629-42 [PMID: 17178155]
  30. J Am Chem Soc. 2011 Jan 19;133(2):172-5 [PMID: 21158438]
  31. Arch Pharm Res. 2005 Jul;28(7):823-8 [PMID: 16114498]
  32. ACS Nano. 2008 May;2(5):889-96 [PMID: 19206485]
  33. Sci Rep. 2016 Apr 27;6:24888 [PMID: 27118152]
  34. Langmuir. 2013 Feb 12;29(6):1779-89 [PMID: 23305179]
  35. Biofactors. 2013 Jan-Feb;39(1):56-68 [PMID: 23303705]
  36. Acta Med Iran. 2013;51(9):591-8 [PMID: 24338188]
  37. Small. 2016 Jun;12(21):2893-905 [PMID: 27079833]
  38. Food Chem Toxicol. 2019 Jun;128:240-255 [PMID: 30991130]
  39. Int J Mol Sci. 2013 Jul 31;14(8):15910-30 [PMID: 23912234]
  40. Soft Matter. 2014 Sep 21;10(35):6820-30 [PMID: 25082426]

MeSH Term

Humans
Female
Curcumin
Silicon Dioxide
Breast Neoplasms
Magnetite Nanoparticles
Silymarin
Nanoparticles

Chemicals

Curcumin
Silicon Dioxide
Magnetite Nanoparticles
Silymarin

Word Cloud

Created with Highcharts 10.0.0NPsSPIONsMRIsilicabreastcancercellularironoxidenanoparticlestheranosticpropertiescoatedmSiO2@SPIONscontainingcurcuminsilymarinpreparedMCF-7druguptakeMesoporousINTRODUCTION:Super-paramagneticknownpromisingnano-drugcarriersmagneticresonanceimagingApplyingherbaceouscomponentscytotoxiceffectscargoscansuggestnewapproachfieldcancer-therapystudymesoporousCURSILevaluatedcelllineMETHODS:NanoparticlesformulatedreversemicroemulsionmethodcharacterizedDLSSEMVSMvitroreleasecytotoxicitydeterminedwellcellsinvestigatedLysoTrackerRedstainingusingconfocalmicroscopyRESULTS:MTTresultsshowedIC50CUR + SILloadedreduced50%comparisonfreemixtureindicatedproperfeaturesendocytosisCONCLUSION:conclusionformulationmayoffernovelsystemresearchesintendedtherapyCurcuminSilymarinSuperparamagneticTheranostic

Similar Articles

Cited By